.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Fuji
US Army
Julphar
AstraZeneca
Merck
Fish and Richardson
Mallinckrodt
Farmers Insurance
Queensland Health

Generated: September 26, 2017

DrugPatentWatch Database Preview

TIKOSYN Drug Profile

« Back to Dashboard

What is the patent landscape for Tikosyn, and when can generic versions of Tikosyn launch?

Tikosyn is a drug marketed by Pfizer and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-two patent family members in forty-six countries.

The generic ingredient in TIKOSYN is dofetilide. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dofetilide profile page.

Summary for Tradename: TIKOSYN

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list60
Clinical Trials: see list4
Patent Applications: see list1,483
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TIKOSYN at DailyMed

Pharmacology for Tradename: TIKOSYN

Drug ClassAntiarrhythmic
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931-001Oct 1, 1999ABRXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931-002Oct 1, 1999ABRXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931-003Oct 1, 1999ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TIKOSYN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931-001Oct 1, 1999► Subscribe► Subscribe
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931-003Oct 1, 1999► Subscribe► Subscribe
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931-002Oct 1, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TIKOSYN

Drugname Dosage Strength RLD Submissiondate
dofetilideCapsules0.125 mg, 0.25 mg, and 0.5 mgTikosyn5/1/2014

International Patent Family for Tradename: TIKOSYN

Country Document Number Estimated Expiration
Panama8462001► Subscribe
Canada2307121► Subscribe
Bulgaria104373► Subscribe
Slovenia1027329► Subscribe
Austria232199► Subscribe
Iceland2179► Subscribe
Malaysia123352► Subscribe
Spain2190620► Subscribe
Colombia4970768► Subscribe
Norway20002191► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TIKOSYN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB00/005United Kingdom► SubscribePRODUCT NAME: DOFETILIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/99/121/001 19991129; UK EU/1/99/121/002 19991129; UK EU/1/99/121/003 19991129; UK EU/1/99/121/004 19991129; UK EU/1/99/121/005 19991129; UK EU/1/99/121/006 19991129; UK EU/1/99/121/007 19991129; UK EU/1/99/121/008 19991129; UK EU/1/99/121/009 19991129; UK EU/1/99/121/010 19991129; UK EU/1/99/121/011 19991129; UK EU/1/99/121/012 19991129; UK EU/1/99/121/013 19991129; UK EU/1/99/121/014 19991129; UK EU/1/99/121/015 19991129
00002Netherlands► SubscribePRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129
00C/005Belgium► SubscribePRODUCT NAME: DOFETILIDE; REGISTRATION NO/DATE: EU/1/99/121/001 19991129
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Baxter
Daiichi Sankyo
Citi
Chinese Patent Office
McKinsey
US Department of Justice
Julphar
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot